Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Axpaxli

Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug

Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.  
Eydenzelt receives FDA approval for four retinal diseases
diabetic macular edema

Eydenzelt receives FDA approval for four retinal diseases

Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following reetinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Cancer drug may also be a possible treatment for age-related macular degeneration
intravitreal injections

Cancer drug may also be a possible treatment for age-related macular degeneration

Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.